Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial - CNBC
- Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial CNBC
- Lilly weight loss drug prevents diabetes, company says USA TODAY
- Lilly’s Zepbound Cut Risk of Diabetes by 94% in Obese People Bloomberg
- Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight Investors | Eli Lilly and Company
- Lilly’s Zepbound slashed risk of developing diabetes STAT